7 reasons to rethink your point-solution cancer benefits

Over the past decade, employers have added cancer screenings, navigation vendors, Centers of Excellence, and advocacy programs to their health plans with the goal of improving outcomes and controlling costs. Instead, many are now managing a fragmented system of point solutions while oncology spend continues to rise.

When cancer care is fragmented, employees move between multiple vendors with little clinical coordination along the way. That lack of integration can lead to delayed follow-up, inconsistent care experiences, and limited visibility into outcomes or ROI.

As a result, many self-insured employers are reevaluating traditional cancer benefits models and looking for more integrated approaches. Color’s Virtual Cancer Clinic combines employee engagement, oncologist-led care, and clinical follow-up within a single model. Color’s employer clients have reported up to a 77% improvement in screening adherence and a 55% reduction in time to diagnosis and treatment.

If cancer benefits aren’t delivering clinical outcomes and cost savings, employers should take a look at the top seven reasons why their point-solution program may be falling short.

#1: Low employee engagement

One of the clearest signs a program is underperforming is low employee engagement, or the percentage of eligible employees who actively enroll in or use the benefit. 

Many traditional point solutions rely on passive enrollment strategies that expect employees to seek support on their own. However, employees dealing with cancer risk, abnormal screenings, or active treatment often need proactive outreach and simple access pathways.

Low engagement is commonly tied to:

• Poor program awareness

• Disconnected vendors

• Complicated enrollment experiences

• Lack of trust in standalone tools

According to Color’s employer engagement data, programs with stronger participation rates typically use multiple communication channels, including:

• Email and SMS outreach

• Direct mail campaigns

• QR-code driven enrollment

• Onsite engagement events

When participation remains low, employers are less likely to improve screening adherence, catch cancer earlier, or generate meaningful cancer benefit ROI. 

#2: Low cancer screening adherence

Screening adherence refers to the percentage of eligible individuals who complete recommended cancer screenings within evidence-based guideline timelines. While many employer cancer programs promote screenings, there is still opportunity to increase screening completion rates. 

Poor screening adherence can contribute to:

• Later-stage diagnoses

• Higher treatment costs

• Increased absenteeism

• Greater disability-related expenses

Screenings matter because they can lead to early detection, which is one of the most effective ways to improve outcomes and lower long-term treatment costs. According to the American Cancer Society screening guidelines, timely screenings play a critical role in identifying cancer earlier, when treatment is often less intensive and more successful. The National Cancer Institute also emphasizes the value of evidence-based screening programs in improving cancer outcomes.

Color reports up to a 77% improvement in screening adherence among employer clients using coordinated outreach and clinical follow-up models. If cancer solutions stop after awareness campaigns or test-kit distribution, employers may consider a model that ensures employees complete follow-up care.

#3: No clinical follow-up for abnormal results

When an employee receives an abnormal screening result, diagnostic testing, specialist referral, diagnosis, and treatment planning are critical next steps. With a point-solution program, employees are left to navigate care on their own, leading to delays and confusion during a critical point in the care journey. 

Programs without structured follow-up systems may see:

• Delayed diagnoses

• Advanced-stage cancer presentations

• Higher emergency care utilization

• Avoidable healthcare spending

With a clinically integrated care model, patients receive clinical follow-up and can count on expert support to coordinate referrals, imaging appointments, and other important next steps.

Color’s oncologist-led model provides 100% clinical management and follow-up on abnormal screening results. 

Identifying risk is just the first step. Employers should also ensure employees successfully move into appropriate care pathways once risk is identified. You can read more about this approach in Color’s Virtual Cancer Clinic model.

#4: No speciality care oversight

Many cancer navigation vendors provide administrative guidance but not direct clinical management. That distinction becomes increasingly important as cancer care grows more specialized and complex.

Clinical oversight refers to the real-time management of cancer care by oncology specialists responsible for treatment guidance, escalation of care, symptom management, and coordination across the care journey. Navigation-only models may help employees understand benefits or schedule appointments, but they often lack the authority to directly intervene in care decisions.

Without centralized oncology oversight, employees may:

• Receive inconsistent guidance

• Experience fragmented care pathways

• Struggle with unmanaged symptoms

• Encounter delays between providers

The NCCN Guidelines continue to reinforce the importance of evidence-based, guideline-concordant cancer care. As a result, many employers are moving beyond referral-only navigation models and prioritizing programs that provide direct oncologist involvement throughout the care journey.

#5: Delays in diagnosis and treatment

Delays in cancer care can significantly affect both clinical outcomes and employer costs. Time to diagnosis refers to the period between an abnormal finding and confirmed diagnosis with treatment planning.

When employees have to navigate disconnected vendors to coordinate imaging, referrals, specialist appointments, and insurance approvals, they’re more likely to experience delays and frustration during a vulnerable time.  These delays can ultimately lead to disease progression, higher claims costs, and increased absenteeism. According to the CDC’s cancer productivity research, cancer-related productivity loss continues to create a substantial economic burden for employers.

Common causes of delay include:

• Referral bottlenecks

• Poor follow-up coordination

• Delayed imaging approvals

• Lack of physician intervention authority

• Vendor fragmentation

Color’s employer clients have experienced approximately a 55% reduction in time to diagnosis and treatment through integrated care coordination. Plus, employees feel more supported.

#6: Overlooked survivorship support

Cancer care strategies that go beyond screening and active treatment can help lower employer and employee long-term risks. That means offering continued clinical care once treatment ends, also known as survivorship support.

Survivorship care includes the ongoing medical, emotional, and psychosocial support individuals may need after initial cancer treatment. Many survivors continue managing chronic symptoms, mental health challenges, recurrence risk, and return-to-work difficulties long after active treatment is complete.

According to Color’s employer materials, nearly 25% of cancer patients experience mental health conditions, while many never receive appropriate support.

Strong survivorship programs may include:

• Symptom monitoring

• Follow-up care coordination

• Mental health support

• Return-to-work planning

• Ongoing oncology guidance

Employers evaluating cancer benefits should consider whether their current strategy supports employees across the full continuum of care rather than focusing only on diagnosis and treatment. Additional employer oncology resources are available through Color’s content library.

#7: Unclear program ROI

If a vendor cannot clearly demonstrate measurable outcomes, employers may struggle to justify continued investment. Return on investment in employer healthcare refers to the financial and clinical value generated relative to program cost.

Many cancer point solutions focus heavily on engagement metrics or anecdotal success stories while offering limited visibility into claims reduction, screening improvements, care gap closure, or productivity outcomes. Employers increasingly need more concrete evidence that a program is improving care while helping manage oncology spend.

Color reports:

• A 2.8:1 ROI in year one

• More than 75% of critical care gaps closed

• More than $8,000 in savings per patient through guideline-based care pathways

When evaluating vendors, employers should ask for measurable outcomes related to:

• Screening adherence

• Time to diagnosis

• ER utilization

• Guideline-concordant care

• Productivity impact

• Oncology cost reduction

Additional insights on evolving employer cancer strategies can be found in Waiting costs more: evolving cancer strategy.

Rethinking employer cancer benefits strategy

Many employers now manage multiple disconnected cancer vendors across screening, navigation, treatment support, and survivorship. While these programs may address specific gaps, they often create fragmented employee experiences and unclear accountability.

Integrated cancer care models are increasingly emerging as an alternative to traditional point solutions by combining:

• Proactive engagement

• Clinical oversight

• Coordinated follow-up

• Survivorship support

• Measurable outcomes reporting

As cancer costs continue rising, employers are looking for strategies that not only improve employee outcomes but also create stronger clinical and financial alignment across the entire cancer journey.